dr. younes discusses ibrutinib plus nivolumab in nhl
Published 6 years ago • 91 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:13
dr. younes on r-chop in combination with ibrutinib in dlbcl
-
1:21
dr. younes discusses fda approval of nivolumab in hodgkin lymphoma
-
1:02
dr. younes on the implications of ibrutinib's approval for patients with mcl
-
1:14
dr. zelenetz on nivolumab plus ibrutinib in patients with cll
-
1:10
dr. younes discusses the future of treating lymphoid malignancies
-
0:54
dr. younes on brentuximab plus avd vs abvd in classical hodgkin lymphoma
-
13:32
my cancer journey: lymphoma symptoms and diagnosis | my cancer story part 1
-
4:38
advocating for hodgkin lymphoma care: jenny's immunotherapy story
-
1:00:50
hodgkin's lymphoma
-
1:09
results for the combination of nivolumab and ibrutinib in non-hodgkin lymphoma and cll
-
1:12
dr. younes on the approval of ibrutinib for mcl
-
1:04
dr. younes on idelalisib in cll and inhl
-
0:51
dr. yasenchak on brentuximb vedotin plus nivolumab in hodgkin lymphoma
-
0:59
dr. yasenchak on the safety profile of brentuximab vedotin/nivolumab in hodgkin lymphoma
-
4:30
the role of ibrutinib in follicular lymphoma
-
2:41
dr. younes on atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma
-
1:37
dr. leonard on ibrutinib combined with chemotherapy in follicular lymphoma
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
5:55
ian flinn, md: bendamustine plus rituxmab outperforms r-chop in long-term bright follow-up
-
0:56
dr. younes discusses abvd versus a avd as front-line treatment in hodgkin lymphoma
-
1:46
philemon trial: ibrutinib, lenalidomide and rituximab in r/r mcl
-
0:35
nivolumab and pembrolizumab and the current treatment landscape for hodgkin lymphoma